Inhibrx Biosciences (INBX) Income from Continuing Operations (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Income from Continuing Operations came in at 32834000.0 in Q4 2025, up 31.4% year-on-year from 24987271.21 in Q4 2024, and up 6.87% on a QoQ basis from 35256000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Income from Continuing Operations (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Income from Continuing Operations data on file, last reported at 32834000.0 in Q4 2025.
- On a quarterly basis, Income from Continuing Operations rose 31.4% year-over-year to 32834000.0 in Q4 2025; TTM through Dec 2025 was 140055000.0, a 108.3% decrease from a year earlier, with the FY2025 full-year figure at 140055000.0, down 108.3% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 32834000.0, up from 35256000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for INBX reached as high as 1858011000.0 in Q2 2024 and fell as low as 91970000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 123336909.09 across 3 years, with a median of 43864000.0 in 2024.
- Across the five-year window, Income from Continuing Operations jumped 4048.85% in 2024 and slumped 101.54% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 91970000.0 in 2023, then surged by 47.96% to 47865000.0 in 2024, then soared by 31.4% to 32834000.0 in 2025.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 32834000.0 in Q4 2025, 35256000.0 in Q3 2025, and 28654000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | -32.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -32.83 Mn |
| Sep 30, 2025 | -35.26 Mn |
| Jun 30, 2025 | -28.65 Mn |
| Mar 31, 2025 | -43.31 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -43.86 Mn |
| Jun 30, 2024 | 1.86 Bn |
| Mar 31, 2024 | -78.71 Mn |
| Dec 31, 2023 | -91.97 Mn |
| Sep 30, 2023 | -51.79 Mn |
| Jun 30, 2023 | -47.05 Mn |